NLRP3 and Alzheimer disease: found that Angelica Yinzi (AYZ) could inhibit the activation of the NLRP3 inflammasome and MAPKs/NF-κB signaling, effectively downregulating the expression of NLRP3, ASC, Caspase-1, and IL-1β in the dorsal skin of mice after treatment, and effectively suppressing AD-induced skin inflammation (137).